A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal biological dose (OBD). In Phase 1b, the recommended phase 2 dose (RP2D) chosen from Phase 1a will be evaluated to further investigate safety, tolerability, pharmacokinetic (PK) and anti-tumor efficacy of ITC-6146RO.

Trial Details

NCT ID
NCT07423117
Phase
PHASE1
Sponsor
IntoCell, Inc
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • ITC-6146RO
Locations (sample)
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Seoul, Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Adult males and females aged ≥ 19 years (Korea) or ≥ 18 years (United States)
  • Patients must be individuals who have voluntarily agreed to participate in the study after receiving a detailed explanation and fully understanding…
  • Pathological confirmation of malignancy and evidence of metastatic or surgically unresectable disease
  • Patients must have at least one evaluable or measurable lesion based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →